SK biotek

SK biotek Ireland & SK biotek Korea are part of the SK pharmteco group. SK pharmteco is the single market-facing team comprised of SK biotek and AMPAC Fine Chemicals. Creating substantial market synergies in the API CDMO space by combining highly complementary assets and expertise this union enables us to provide the highest-quality services to our customers. SK pharmteco is a subsidiary of the Korean conglomerate SK, a global leader in energy, chemicals and IT; it is the cornerstone of SK holdings growth strategy. With world-class state-of-the-art facilities and technology, increased capabilities: energetic chemistry, continuous flow process, controlled substances, particle engineering, high potency - with world-class potent handling capability (down to low nanogram per cubic meter levels). We have multiple cGMP manufacturing and development sites, with over 1020m³ of capacity among 6 sites including USA, Korea and Ireland.Our scientists and engineers are leaders in continuous manufacturing methodologies (tubular and fixed bed reactions and CSTRs), having successfully developed processes from low kilograms through to 10s of tonnes. In addition to providing analytical development and validation for all of the products that we manufacture in our global network,As leaders in operational excellence and continuous improvement and boast exceptional technical capabilities. The global presence of our highly skilled and experienced team offers total support from development through to commercial project transfer and management plus flexibility in R&D and manufacturing. All our plants have been approved by global regulatory agencies including the FDA, EMEA, PDMA and Korean MFDS.We specialize in the commercial and clinical production of APIs, Advanced Intermediates, Highly Potent APIs, Registered Starting Materials and Key Building Blocks. Our offering includes process R&D analytical method development, scale-up and optimization, validation and stability